CG Labz
Peptide Library / Metabolic / Weight Management

AOD-9604

hGH Fragment 176-191

AOD-9604 Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

AOD-9604 is a modified fragment of the C-terminus (residues 176–191) of human growth hormone. It was engineered to retain the fat-metabolising activity of GH while lacking the effects on blood glucose and IGF-1 associated with the full hormone.

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Literature Range
250–300 mcg per administration
Measuring Reference
At 2.5 mg/mL: 300 mcg = 0.12 mL = 12 units
Frequency
Once daily
Route (studies)
Subcutaneous
Cycle
8–12 weeks

Scientific Data

Molecular Formula
—
Molecular Weight
1815.1 Da
Sequence
hGH(176-191)
Sequence Length
3
CAS
Research compound
Peptide Family
GH fragment
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.120 mL
Syringe Units
12.0 U
Doses / Vial
16

Units assume a U-100 insulin syringe (100 units = 1 mL). Often dosed fasted in the morning; does not raise IGF-1 in studies.

Frequency: Once daily, fasted

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 12-week protocol at approximately 300 mcg per day.

Peptide (5 mg vials)
Estimate vials from total mass: 300 mcg/day × 84 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model GH-fragment lipolysis without glycemic/IGF-1 effects.
Schedule
Daily, 8–12 weeks.
Dose Range
250–300 mcg/day.

Dosing Protocol

Start
250–300 mcg once daily
Target Range
300 mcg/day
Frequency
Once daily, fasted morning common
Cycle Length
8–12 weeks
Timing
Fasted administration is typical in protocols
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Marketed-grade human fat-loss evidence is limited; treat expectations accordingly.
  • Fasted dosing is common in protocols.

How This Works

AOD-9604 mimics the lipolytic C-terminal region of GH, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis in adipose tissue without binding the GH receptor in a way that alters glucose metabolism or raises IGF-1. Preclinical work suggests it acts partly through β3-adrenergic pathways in fat cells.

Potential Benefits & Side Effects

Reported in research
  • Stimulated lipolysis and reduced lipogenesis in fat models
  • No measured impact on blood glucose or IGF-1 in studies
  • Investigated for cartilage/osteoarthritis repair as well
  • Favourable tolerability profile
Possible considerations
  • Generally mild; injection-site reactions
  • Headache or fatigue in some reports
  • Human efficacy data for fat loss is limited/mixed
  • Not an approved weight-loss drug

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Diabetes, Obesity & Metabolism
    Heffernan M. et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism.
    View Source